258 related articles for article (PubMed ID: 15217611)
21. Inside the Hsp90 inhibitors binding mode through induced fit docking.
Lauria A; Ippolito M; Almerico AM
J Mol Graph Model; 2009 Feb; 27(6):712-22. PubMed ID: 19084447
[TBL] [Abstract][Full Text] [Related]
22. Heat shock protein 90 regulates development in Dictyostelium discoideum.
Sawarkar R; Roy N; Rao S; Raman S; Venketesh S; Suguna K; Tatu U
J Mol Biol; 2008 Oct; 383(1):24-35. PubMed ID: 18718841
[TBL] [Abstract][Full Text] [Related]
23. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Xu W; Yuan X; Xiang Z; Mimnaugh E; Marcu M; Neckers L
Nat Struct Mol Biol; 2005 Feb; 12(2):120-6. PubMed ID: 15643424
[TBL] [Abstract][Full Text] [Related]
24. Some sulfonamide drugs inhibit ATPase activity of heat shock protein 90: investigation by docking simulation and experimental validation.
Sheikha GA; Al-Sha'er MA; Taha MO
J Enzyme Inhib Med Chem; 2011 Oct; 26(5):603-9. PubMed ID: 21190426
[TBL] [Abstract][Full Text] [Related]
25. Principal component analysis on molecular descriptors as an alternative point of view in the search of new Hsp90 inhibitors.
Lauria A; Ippolito M; Almerico AM
Comput Biol Chem; 2009 Oct; 33(5):386-90. PubMed ID: 19660987
[TBL] [Abstract][Full Text] [Related]
26. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
28. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
29. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue.
McDowell CL; Bryan Sutton R; Obermann WM
Int J Biol Macromol; 2009 Oct; 45(3):310-4. PubMed ID: 19576239
[TBL] [Abstract][Full Text] [Related]
30. Biochemical and structural studies of the interaction of Cdc37 with Hsp90.
Zhang W; Hirshberg M; McLaughlin SH; Lazar GA; Grossmann JG; Nielsen PR; Sobott F; Robinson CV; Jackson SE; Laue ED
J Mol Biol; 2004 Jul; 340(4):891-907. PubMed ID: 15223329
[TBL] [Abstract][Full Text] [Related]
31. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.
Huth JR; Park C; Petros AM; Kunzer AR; Wendt MD; Wang X; Lynch CL; Mack JC; Swift KM; Judge RA; Chen J; Richardson PL; Jin S; Tahir SK; Matayoshi ED; Dorwin SA; Ladror US; Severin JM; Walter KA; Bartley DM; Fesik SW; Elmore SW; Hajduk PJ
Chem Biol Drug Des; 2007 Jul; 70(1):1-12. PubMed ID: 17630989
[TBL] [Abstract][Full Text] [Related]
32. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.
Goode KM; Petrov DP; Vickman RE; Crist SA; Pascuzzi PE; Ratliff TL; Davisson VJ; Hazbun TR
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1992-2006. PubMed ID: 28495207
[TBL] [Abstract][Full Text] [Related]
34. Discovery and development of purine-scaffold Hsp90 inhibitors.
Chiosis G
Curr Top Med Chem; 2006; 6(11):1183-91. PubMed ID: 16842155
[TBL] [Abstract][Full Text] [Related]
35. [Progress in the study of heat shock protein 90 inhibitors].
Luo HM; Sun W; Yin JY; Yang XH
Yao Xue Xue Bao; 2010 Jul; 45(7):813-20. PubMed ID: 20931776
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery.
Burlison JA; Blagg BS
Org Lett; 2006 Oct; 8(21):4855-8. PubMed ID: 17020320
[TBL] [Abstract][Full Text] [Related]
37. 7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.
Zhang L; Fan J; Vu K; Hong K; Le Brazidec JY; Shi J; Biamonte M; Busch DJ; Lough RE; Grecko R; Ran Y; Sensintaffar JL; Kamal A; Lundgren K; Burrows FJ; Mansfield R; Timony GA; Ulm EH; Kasibhatla SR; Boehm MF
J Med Chem; 2006 Aug; 49(17):5352-62. PubMed ID: 16913725
[TBL] [Abstract][Full Text] [Related]
38. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.
Shin SC; El-Damasy AK; Lee JH; Seo SH; Kim JH; Seo YH; Lee Y; Yu JH; Bang EK; Kim EE; Keum G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317068
[TBL] [Abstract][Full Text] [Related]
39. Hsp90 inhibitors identified from a library of novobiocin analogues.
Yu XM; Shen G; Neckers L; Blake H; Holzbeierlein J; Cronk B; Blagg BS
J Am Chem Soc; 2005 Sep; 127(37):12778-9. PubMed ID: 16159253
[TBL] [Abstract][Full Text] [Related]
40. Dynamics of conserved waters in human Hsp90: implications for drug design.
Yan A; Grant GH; Richards WG
J R Soc Interface; 2008 Dec; 5 Suppl 3(Suppl 3):S199-205. PubMed ID: 18826913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
